View ValuationAnhui Anke Biotechnology (Group) 향후 성장Future 기준 점검 1/6Anhui Anke Biotechnology (Group) (는) 각각 연간 11.5% 및 9.7% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 11.5% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 16.5% 로 예상됩니다.핵심 정보11.5%이익 성장률11.52%EPS 성장률Biotechs 이익 성장29.2%매출 성장률9.7%향후 자기자본이익률16.52%애널리스트 커버리지Low마지막 업데이트07 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Jul 01Anhui Anke Biotechnology (Group) Co., Ltd. to Report First Half, 2026 Results on Aug 26, 2026Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report first half, 2026 results on Aug 26, 2026Declared Dividend • May 27Dividend of CN¥0.25 announcedShareholders will receive a dividend of CN¥0.25. Ex-date: 29th May 2026 Payment date: 29th May 2026 Dividend yield will be 3.0%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (60% earnings payout ratio) and cash flows (61% cash payout ratio). The dividend has increased by an average of 20% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 11% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 8 non-independent directors. Independent Director Lu Shi Yao was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공고 • Mar 31+ 1 more updateAnhui Anke Biotechnology (Group) Co., Ltd. to Report Q1, 2026 Results on Apr 24, 2026Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report Q1, 2026 results on Apr 24, 2026공고 • Dec 31Anhui Anke Biotechnology (Group) Co., Ltd. to Report Fiscal Year 2025 Results on Mar 31, 2026Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report fiscal year 2025 results on Mar 31, 2026공고 • Sep 30Anhui Anke Biotechnology (Group) Co., Ltd. to Report Q3, 2025 Results on Oct 28, 2025Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025공고 • Jul 02Anhui Anke Biotechnology (Group) Co., Ltd. to Report First Half, 2025 Results on Aug 22, 2025Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report first half, 2025 results on Aug 22, 2025공고 • Apr 23Anhui Anke Biotechnology (Group) Co., Ltd. Approves Profit Distribution for 2024Anhui Anke Biotechnology (Group) Co., Ltd. at its Annual General Meeting of 2024 held on 18 April 2025, approved 2024 profit distribution plan with Cash dividend/10 shares (tax included): CNY 1.50000000.공고 • Mar 31Anhui Anke Biotechnology (Group) Co., Ltd. to Report Q1, 2025 Results on Apr 29, 2025Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025공고 • Mar 30Anhui Anke Biotechnology (Group) Co., Ltd. Proposes Final Cash Dividend for the Year 2024Anhui Anke Biotechnology (Group) Co., Ltd. announced on 28 March 2025 the profit distribution proposal for 2024 as follows: Final Cash dividend per 10 shares (tax included) of CNY 1.50000000.공고 • Mar 28Anhui Anke Biotechnology (Group) Co., Ltd., Annual General Meeting, Apr 18, 2025Anhui Anke Biotechnology (Group) Co., Ltd., Annual General Meeting, Apr 18, 2025, at 09:30 China Standard Time. Location: The Company's Meeting Room, Hefei, Anhui China공고 • Jan 09Anhui Anke Biotechnology (Group) Co., Ltd. Approves Cash Dividend for Third Quarter of 2024Anhui Anke Biotechnology (Group) Co., Ltd. in its Extraordinary General Meeting of 2025 on 7 January 2025 approved Cash dividend/10 shares (tax included) of CNY 1.00000000 for third quarter of 2024.공고 • Dec 31Anhui Anke Biotechnology (Group) Co., Ltd. to Report Fiscal Year 2024 Results on Mar 28, 2025Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report fiscal year 2024 results on Mar 28, 2025공고 • Dec 21Anhui Anke Biotechnology (Group) Co., Ltd. Proposes Dividend for the Third Quarter of 2024Anhui Anke Biotechnology (Group) Co., Ltd. announced on 20 December 2024 the profit distribution proposal for the third quarter of 2024 as follows: Cash dividend/10 shares (tax included): CNY 1.0.Reported Earnings • Oct 25Third quarter 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.15 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.10 (down from CN¥0.15 in 3Q 2023). Revenue: CN¥622.5m (down 15% from 3Q 2023). Net income: CN¥173.6m (down 33% from 3Q 2023). Profit margin: 28% (down from 35% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to CN¥8.99, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 25x in the Biotechs industry in China. Total loss to shareholders of 24% over the past three years.공고 • Sep 30Anhui Anke Biotechnology (Group) Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report Q3, 2024 results on Oct 25, 2024Valuation Update With 7 Day Price Move • Sep 27Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥8.73, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 21x in the Biotechs industry in China. Total loss to shareholders of 21% over the past three years.Reported Earnings • Aug 28Second quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.13 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.12 (down from CN¥0.13 in 2Q 2023). Revenue: CN¥642.7m (down 7.3% from 2Q 2023). Net income: CN¥198.4m (down 5.9% from 2Q 2023). Profit margin: 31% (in line with 2Q 2023). Revenue is forecast to grow 24% p.a. on average during the next 2 years, compared to a 24% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.공고 • Jun 29Anhui Anke Biotechnology (Group) Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report first half, 2024 results on Aug 28, 2024Declared Dividend • May 23Dividend of CN¥0.25 announcedDividend of CN¥0.25 is the same as last year. Ex-date: 27th May 2024 Payment date: 27th May 2024 Dividend yield will be 2.5%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (47% earnings payout ratio) and cash flows (59% cash payout ratio). The dividend has increased by an average of 22% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 16% over the next year, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Apr 26First quarter 2024 earnings released: EPS: CN¥0.13 (vs CN¥0.11 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.13 (up from CN¥0.11 in 1Q 2023). Revenue: CN¥656.1m (up 10% from 1Q 2023). Net income: CN¥217.7m (up 17% from 1Q 2023). Profit margin: 33% (up from 31% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.공고 • Mar 30Anhui Anke Biotechnology (Group) Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024공고 • Mar 28Anhui Anke Biotechnology (Group) Co., Ltd., Annual General Meeting, Apr 18, 2024Anhui Anke Biotechnology (Group) Co., Ltd., Annual General Meeting, Apr 18, 2024, at 09:30 China Standard Time. Location: The Company's Meeting Room, Hefei, Anhui ChinaReported Earnings • Mar 28Full year 2023 earnings released: EPS: CN¥0.51 (vs CN¥0.43 in FY 2022)Full year 2023 results: EPS: CN¥0.51 (up from CN¥0.43 in FY 2022). Revenue: CN¥2.87b (up 23% from FY 2022). Net income: CN¥847.2m (up 21% from FY 2022). Profit margin: 30% (in line with FY 2022). Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Feb 07Investor sentiment improves as stock rises 20%After last week's 20% share price gain to CN¥9.84, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 20x in the Biotechs industry in China. Total loss to shareholders of 20% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥17.03 per share.공고 • Dec 29Anhui Anke Biotechnology (Group) Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report fiscal year 2023 results on Mar 28, 2024Board Change • Oct 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 8 non-independent directors. Independent Director Feihu Chen was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 25Third quarter 2023 earnings released: EPS: CN¥0.15 (vs CN¥0.15 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.15 (up from CN¥0.15 in 3Q 2022). Revenue: CN¥734.1m (up 17% from 3Q 2022). Net income: CN¥258.1m (up 3.3% from 3Q 2022). Profit margin: 35% (down from 40% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.공고 • Sep 30Anhui Anke Biotechnology (Group) Co., Ltd. to Report Q3, 2023 Results on Oct 25, 2023Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report Q3, 2023 results on Oct 25, 2023Reported Earnings • Aug 24Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.10 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.13 (up from CN¥0.10 in 2Q 2022). Revenue: CN¥693.1m (up 27% from 2Q 2022). Net income: CN¥210.7m (up 23% from 2Q 2022). Profit margin: 30% (in line with 2Q 2022). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 29Full year 2022 earnings released: EPS: CN¥0.43 (vs CN¥0.13 in FY 2021)Full year 2022 results: EPS: CN¥0.43 (up from CN¥0.13 in FY 2021). Revenue: CN¥2.33b (up 7.5% from FY 2021). Net income: CN¥703.3m (up 240% from FY 2021). Profit margin: 30% (up from 9.5% in FY 2021). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 27% p.a. on average during the next 2 years, compared to a 24% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Dec 13Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥11.39, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 30x in the Biotechs industry in China. Total returns to shareholders of 22% over the past three years.Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 4 independent directors. 8 non-independent directors. Non-Independent Director Zhen Xu was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Reported Earnings • Oct 27Third quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.11 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.15 (up from CN¥0.11 in 3Q 2021). Revenue: CN¥626.0m (up 8.3% from 3Q 2021). Net income: CN¥249.8m (up 35% from 3Q 2021). Profit margin: 40% (up from 32% in 3Q 2021). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Reported Earnings • Aug 26Second quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.075 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.10 (up from CN¥0.075 in 2Q 2021). Revenue: CN¥547.4m (up 13% from 2Q 2021). Net income: CN¥171.5m (up 45% from 2Q 2021). Profit margin: 31% (up from 24% in 2Q 2021). Over the next year, revenue is forecast to grow 32%, compared to a 33% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 29First quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.075 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.11 (up from CN¥0.075 in 1Q 2021). Revenue: CN¥533.4m (up 10.0% from 1Q 2021). Net income: CN¥172.9m (up 38% from 1Q 2021). Profit margin: 32% (up from 26% in 1Q 2021). Over the next year, revenue is forecast to grow 28%, compared to a 47% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 4 independent directors. 8 non-independent directors. Non-Independent Director Zhen Xu was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Reported Earnings • Apr 03Full year 2021 earnings released: EPS: CN¥0.13 (vs CN¥0.22 in FY 2020)Full year 2021 results: EPS: CN¥0.13 (down from CN¥0.22 in FY 2020). Revenue: CN¥2.17b (up 28% from FY 2020). Net income: CN¥206.6m (down 42% from FY 2020). Profit margin: 9.5% (down from 21% in FY 2020). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Jan 21Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to CN¥11.27, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 34x in the Biotechs industry in China. Total returns to shareholders of 38% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥18.44 per share.Reported Earnings • Oct 31Third quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.084 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥578.2m (up 31% from 3Q 2020). Net income: CN¥185.4m (up 36% from 3Q 2020). Profit margin: 32% (up from 31% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.Reported Earnings • Aug 22Second quarter 2021 earnings released: EPS CN¥0.075 (vs CN¥0.049 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥484.4m (up 22% from 2Q 2020). Net income: CN¥118.4m (up 46% from 2Q 2020). Profit margin: 24% (up from 20% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 9% per year.Valuation Update With 7 Day Price Move • May 24Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to CN¥15.00, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 47x in the Biotechs industry in China. Total returns to shareholders of 27% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥22.34 per share.Reported Earnings • Apr 30First quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.062 in 1Q 2020)The company reported a solid first quarter result with improved earnings and revenues, although profit margins were flat. First quarter 2021 results: Revenue: CN¥484.8m (up 54% from 1Q 2020). Net income: CN¥125.6m (up 54% from 1Q 2020). Profit margin: 26% (in line with 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.Reported Earnings • Apr 08Full year 2020 earnings released: EPS CN¥0.26 (vs CN¥0.092 in FY 2019)The company reported a decent full year result with improved earnings and profit margins, although revenues were flat. Full year 2020 results: Revenue: CN¥1.70b (flat on FY 2019). Net income: CN¥359.0m (up 188% from FY 2019). Profit margin: 21% (up from 7.3% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Feb 06New 90-day low: CN¥13.69The company is down 17% from its price of CN¥16.55 on 06 November 2020. The Chinese market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.91 per share.Is New 90 Day High Low • Dec 28New 90-day low: CN¥14.64The company is down 10.0% from its price of CN¥16.21 on 30 September 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.83 per share.Is New 90 Day High Low • Dec 12New 90-day low: CN¥14.71The company is down 7.0% from its price of CN¥15.90 on 11 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.87 per share.Is New 90 Day High Low • Nov 25New 90-day low: CN¥15.69The company is down 8.0% from its price of CN¥17.10 on 27 August 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.43 per share.Reported Earnings • Oct 29Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥166.6m, down 42% from the prior year. Total revenue was CN¥1.70b over the last 12 months, up 5.9% from the prior year.이익 및 매출 성장 예측XSEC:300009 - 애널리스트 향후 추정치 및 과거 재무 데이터 (CNY Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20283,365964N/A352112/31/20273,060866N/A1,129112/31/20262,826789N/A1,47213/31/20262,559694679809N/A12/31/20252,647735736863N/A9/30/20252,577669749820N/A6/30/20252,529657717796N/A3/31/20252,509698642726N/A12/31/20242,536707568685N/A9/30/20242,766783596748N/A6/30/20242,877867633826N/A3/31/20242,928879713892N/A12/31/20232,866847758953N/A9/30/20232,646763472883N/A6/30/20232,538755359796N/A3/31/20232,392716291751N/A1/1/20232,331703225699N/A9/30/20222,328372385632N/A6/30/20222,280307448636N/A3/31/20222,217254471673N/A12/31/20212,169207461592N/A9/30/20212,096489509628N/A6/30/20211,959441388509N/A3/31/20211,871403387492N/A12/31/20201,701359326465N/A9/30/20201,702167237400N/A6/30/20201,661140221378N/A3/31/20201,681140161343N/A12/31/20191,713124N/A296N/A9/30/20191,607289N/A257N/A6/30/20191,598280N/A239N/A3/31/20191,529270N/A258N/A12/31/20181,462263N/A287N/A9/30/20181,382317N/A286N/A6/30/20181,276292N/A322N/A3/31/20181,177290N/A305N/A12/31/20171,096278N/A281N/A9/30/20171,009249N/A285N/A6/30/2017941228N/A254N/A3/31/2017878209N/A243N/A12/31/2016849197N/A258N/A9/30/2016751169N/A169N/A6/30/2016696160N/A148N/A3/31/2016671148N/A144N/A12/31/2015636136N/A119N/A9/30/2015629137N/A124N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 300009 의 연간 예상 수익 증가율(11.5%)이 saving rate(2.4%)보다 높습니다.수익 vs 시장: 300009 의 연간 수익(11.5%)이 CN 시장(26.8%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: 300009 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: 300009 의 수익(연간 9.7%)이 CN 시장(연간 17%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: 300009 의 수익(연간 9.7%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 300009의 자본 수익률은 3년 후 16.5%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/17 06:57종가2026/08/17 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Anhui Anke Biotechnology (Group) Co., Ltd.는 5명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Chao LiCitic Securities Co., Ltd.Changyan XieGuosen Securities Co., Ltd.Ye Hui YangHuatai Research2명의 분석가 더 보기
공고 • Jul 01Anhui Anke Biotechnology (Group) Co., Ltd. to Report First Half, 2026 Results on Aug 26, 2026Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report first half, 2026 results on Aug 26, 2026
Declared Dividend • May 27Dividend of CN¥0.25 announcedShareholders will receive a dividend of CN¥0.25. Ex-date: 29th May 2026 Payment date: 29th May 2026 Dividend yield will be 3.0%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (60% earnings payout ratio) and cash flows (61% cash payout ratio). The dividend has increased by an average of 20% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 11% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 8 non-independent directors. Independent Director Lu Shi Yao was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • Mar 31+ 1 more updateAnhui Anke Biotechnology (Group) Co., Ltd. to Report Q1, 2026 Results on Apr 24, 2026Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report Q1, 2026 results on Apr 24, 2026
공고 • Dec 31Anhui Anke Biotechnology (Group) Co., Ltd. to Report Fiscal Year 2025 Results on Mar 31, 2026Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report fiscal year 2025 results on Mar 31, 2026
공고 • Sep 30Anhui Anke Biotechnology (Group) Co., Ltd. to Report Q3, 2025 Results on Oct 28, 2025Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025
공고 • Jul 02Anhui Anke Biotechnology (Group) Co., Ltd. to Report First Half, 2025 Results on Aug 22, 2025Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report first half, 2025 results on Aug 22, 2025
공고 • Apr 23Anhui Anke Biotechnology (Group) Co., Ltd. Approves Profit Distribution for 2024Anhui Anke Biotechnology (Group) Co., Ltd. at its Annual General Meeting of 2024 held on 18 April 2025, approved 2024 profit distribution plan with Cash dividend/10 shares (tax included): CNY 1.50000000.
공고 • Mar 31Anhui Anke Biotechnology (Group) Co., Ltd. to Report Q1, 2025 Results on Apr 29, 2025Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025
공고 • Mar 30Anhui Anke Biotechnology (Group) Co., Ltd. Proposes Final Cash Dividend for the Year 2024Anhui Anke Biotechnology (Group) Co., Ltd. announced on 28 March 2025 the profit distribution proposal for 2024 as follows: Final Cash dividend per 10 shares (tax included) of CNY 1.50000000.
공고 • Mar 28Anhui Anke Biotechnology (Group) Co., Ltd., Annual General Meeting, Apr 18, 2025Anhui Anke Biotechnology (Group) Co., Ltd., Annual General Meeting, Apr 18, 2025, at 09:30 China Standard Time. Location: The Company's Meeting Room, Hefei, Anhui China
공고 • Jan 09Anhui Anke Biotechnology (Group) Co., Ltd. Approves Cash Dividend for Third Quarter of 2024Anhui Anke Biotechnology (Group) Co., Ltd. in its Extraordinary General Meeting of 2025 on 7 January 2025 approved Cash dividend/10 shares (tax included) of CNY 1.00000000 for third quarter of 2024.
공고 • Dec 31Anhui Anke Biotechnology (Group) Co., Ltd. to Report Fiscal Year 2024 Results on Mar 28, 2025Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report fiscal year 2024 results on Mar 28, 2025
공고 • Dec 21Anhui Anke Biotechnology (Group) Co., Ltd. Proposes Dividend for the Third Quarter of 2024Anhui Anke Biotechnology (Group) Co., Ltd. announced on 20 December 2024 the profit distribution proposal for the third quarter of 2024 as follows: Cash dividend/10 shares (tax included): CNY 1.0.
Reported Earnings • Oct 25Third quarter 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.15 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.10 (down from CN¥0.15 in 3Q 2023). Revenue: CN¥622.5m (down 15% from 3Q 2023). Net income: CN¥173.6m (down 33% from 3Q 2023). Profit margin: 28% (down from 35% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to CN¥8.99, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 25x in the Biotechs industry in China. Total loss to shareholders of 24% over the past three years.
공고 • Sep 30Anhui Anke Biotechnology (Group) Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report Q3, 2024 results on Oct 25, 2024
Valuation Update With 7 Day Price Move • Sep 27Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥8.73, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 21x in the Biotechs industry in China. Total loss to shareholders of 21% over the past three years.
Reported Earnings • Aug 28Second quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.13 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.12 (down from CN¥0.13 in 2Q 2023). Revenue: CN¥642.7m (down 7.3% from 2Q 2023). Net income: CN¥198.4m (down 5.9% from 2Q 2023). Profit margin: 31% (in line with 2Q 2023). Revenue is forecast to grow 24% p.a. on average during the next 2 years, compared to a 24% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
공고 • Jun 29Anhui Anke Biotechnology (Group) Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report first half, 2024 results on Aug 28, 2024
Declared Dividend • May 23Dividend of CN¥0.25 announcedDividend of CN¥0.25 is the same as last year. Ex-date: 27th May 2024 Payment date: 27th May 2024 Dividend yield will be 2.5%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (47% earnings payout ratio) and cash flows (59% cash payout ratio). The dividend has increased by an average of 22% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 16% over the next year, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Apr 26First quarter 2024 earnings released: EPS: CN¥0.13 (vs CN¥0.11 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.13 (up from CN¥0.11 in 1Q 2023). Revenue: CN¥656.1m (up 10% from 1Q 2023). Net income: CN¥217.7m (up 17% from 1Q 2023). Profit margin: 33% (up from 31% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
공고 • Mar 30Anhui Anke Biotechnology (Group) Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024
공고 • Mar 28Anhui Anke Biotechnology (Group) Co., Ltd., Annual General Meeting, Apr 18, 2024Anhui Anke Biotechnology (Group) Co., Ltd., Annual General Meeting, Apr 18, 2024, at 09:30 China Standard Time. Location: The Company's Meeting Room, Hefei, Anhui China
Reported Earnings • Mar 28Full year 2023 earnings released: EPS: CN¥0.51 (vs CN¥0.43 in FY 2022)Full year 2023 results: EPS: CN¥0.51 (up from CN¥0.43 in FY 2022). Revenue: CN¥2.87b (up 23% from FY 2022). Net income: CN¥847.2m (up 21% from FY 2022). Profit margin: 30% (in line with FY 2022). Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Feb 07Investor sentiment improves as stock rises 20%After last week's 20% share price gain to CN¥9.84, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 20x in the Biotechs industry in China. Total loss to shareholders of 20% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥17.03 per share.
공고 • Dec 29Anhui Anke Biotechnology (Group) Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report fiscal year 2023 results on Mar 28, 2024
Board Change • Oct 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 8 non-independent directors. Independent Director Feihu Chen was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 25Third quarter 2023 earnings released: EPS: CN¥0.15 (vs CN¥0.15 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.15 (up from CN¥0.15 in 3Q 2022). Revenue: CN¥734.1m (up 17% from 3Q 2022). Net income: CN¥258.1m (up 3.3% from 3Q 2022). Profit margin: 35% (down from 40% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
공고 • Sep 30Anhui Anke Biotechnology (Group) Co., Ltd. to Report Q3, 2023 Results on Oct 25, 2023Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report Q3, 2023 results on Oct 25, 2023
Reported Earnings • Aug 24Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.10 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.13 (up from CN¥0.10 in 2Q 2022). Revenue: CN¥693.1m (up 27% from 2Q 2022). Net income: CN¥210.7m (up 23% from 2Q 2022). Profit margin: 30% (in line with 2Q 2022). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 29Full year 2022 earnings released: EPS: CN¥0.43 (vs CN¥0.13 in FY 2021)Full year 2022 results: EPS: CN¥0.43 (up from CN¥0.13 in FY 2021). Revenue: CN¥2.33b (up 7.5% from FY 2021). Net income: CN¥703.3m (up 240% from FY 2021). Profit margin: 30% (up from 9.5% in FY 2021). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 27% p.a. on average during the next 2 years, compared to a 24% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Dec 13Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥11.39, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 30x in the Biotechs industry in China. Total returns to shareholders of 22% over the past three years.
Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 4 independent directors. 8 non-independent directors. Non-Independent Director Zhen Xu was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Reported Earnings • Oct 27Third quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.11 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.15 (up from CN¥0.11 in 3Q 2021). Revenue: CN¥626.0m (up 8.3% from 3Q 2021). Net income: CN¥249.8m (up 35% from 3Q 2021). Profit margin: 40% (up from 32% in 3Q 2021). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Reported Earnings • Aug 26Second quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.075 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.10 (up from CN¥0.075 in 2Q 2021). Revenue: CN¥547.4m (up 13% from 2Q 2021). Net income: CN¥171.5m (up 45% from 2Q 2021). Profit margin: 31% (up from 24% in 2Q 2021). Over the next year, revenue is forecast to grow 32%, compared to a 33% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 29First quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.075 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.11 (up from CN¥0.075 in 1Q 2021). Revenue: CN¥533.4m (up 10.0% from 1Q 2021). Net income: CN¥172.9m (up 38% from 1Q 2021). Profit margin: 32% (up from 26% in 1Q 2021). Over the next year, revenue is forecast to grow 28%, compared to a 47% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 4 independent directors. 8 non-independent directors. Non-Independent Director Zhen Xu was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Reported Earnings • Apr 03Full year 2021 earnings released: EPS: CN¥0.13 (vs CN¥0.22 in FY 2020)Full year 2021 results: EPS: CN¥0.13 (down from CN¥0.22 in FY 2020). Revenue: CN¥2.17b (up 28% from FY 2020). Net income: CN¥206.6m (down 42% from FY 2020). Profit margin: 9.5% (down from 21% in FY 2020). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Jan 21Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to CN¥11.27, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 34x in the Biotechs industry in China. Total returns to shareholders of 38% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥18.44 per share.
Reported Earnings • Oct 31Third quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.084 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥578.2m (up 31% from 3Q 2020). Net income: CN¥185.4m (up 36% from 3Q 2020). Profit margin: 32% (up from 31% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Aug 22Second quarter 2021 earnings released: EPS CN¥0.075 (vs CN¥0.049 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥484.4m (up 22% from 2Q 2020). Net income: CN¥118.4m (up 46% from 2Q 2020). Profit margin: 24% (up from 20% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 9% per year.
Valuation Update With 7 Day Price Move • May 24Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to CN¥15.00, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 47x in the Biotechs industry in China. Total returns to shareholders of 27% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥22.34 per share.
Reported Earnings • Apr 30First quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.062 in 1Q 2020)The company reported a solid first quarter result with improved earnings and revenues, although profit margins were flat. First quarter 2021 results: Revenue: CN¥484.8m (up 54% from 1Q 2020). Net income: CN¥125.6m (up 54% from 1Q 2020). Profit margin: 26% (in line with 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.
Reported Earnings • Apr 08Full year 2020 earnings released: EPS CN¥0.26 (vs CN¥0.092 in FY 2019)The company reported a decent full year result with improved earnings and profit margins, although revenues were flat. Full year 2020 results: Revenue: CN¥1.70b (flat on FY 2019). Net income: CN¥359.0m (up 188% from FY 2019). Profit margin: 21% (up from 7.3% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Feb 06New 90-day low: CN¥13.69The company is down 17% from its price of CN¥16.55 on 06 November 2020. The Chinese market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.91 per share.
Is New 90 Day High Low • Dec 28New 90-day low: CN¥14.64The company is down 10.0% from its price of CN¥16.21 on 30 September 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.83 per share.
Is New 90 Day High Low • Dec 12New 90-day low: CN¥14.71The company is down 7.0% from its price of CN¥15.90 on 11 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.87 per share.
Is New 90 Day High Low • Nov 25New 90-day low: CN¥15.69The company is down 8.0% from its price of CN¥17.10 on 27 August 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.43 per share.
Reported Earnings • Oct 29Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥166.6m, down 42% from the prior year. Total revenue was CN¥1.70b over the last 12 months, up 5.9% from the prior year.